We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quidel Partners with Global Lyme Alliance, Leads in Lyme Disease Testing

By LabMedica International staff writers
Posted on 14 Jun 2022
Print article
Image: Sofia 2 Lyme FIA is the only FDA-approved rapid POC test on the market (Photo courtesy of Quidel)
Image: Sofia 2 Lyme FIA is the only FDA-approved rapid POC test on the market (Photo courtesy of Quidel)

Lyme disease is a growing epidemic and more than 14% of the world’s population probably has, or has had, the tick-borne disease, as indicated by the presence of antibodies in the blood. Borrelia burgdorferi sensu lato (Bb) infection, more usually known as Lyme disease, is the most common type of tick-borne infection, with ticks second only to mosquitoes in terms of their carriage of harmful microbes. Redness and swelling at the site of the tick bite is typical, but the infecting agent can spread to other tissues and organs, potentially affecting the nervous system, joints, heart and skin. Lyme disease has continued to spread around the world, but there’s no agreement on just how common it is globally, or what the specific risk factors might be.

Now, Quidel Corporation (San Diego, CA, USA) is joining forces with Global Lyme Alliance (Stamford, CT, USA) to heighten public awareness around Lyme disease during Lyme Disease Awareness Month (in May) and beyond. Quidel is the leading developer in the US of the only FDA-approved rapid point of care diagnostic Lyme disease test. As part of its partnership, Quidel serves as GLA’s Official Sponsor during Lyme Awareness Month and will partner on a series of educational PACE accredited webinars. The webinars will provide new information on various Lyme topics in an open discussion format, all designed to bring awareness to Lyme disease, along with rapid ways to diagnose Lyme, leading to prompt treatment.

Leading the way in Lyme disease testing is Quidel’s Sofia 2 Lyme FIA. The only FDA-approved rapid point of care test on the market provides the patient and their physician with indicative results within 15 minutes instead of days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood.

Related Links:
Quidel Corporation 
Global Lyme Alliance 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more